专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

41. 发明公开

US20240100187A1 Antibody Delivery 审中-公开
公开(公告)号：US20240100187A1
公开(公告)日：2024-03-28
申请号：US18039840
申请日：2021-12-17
申请人： AC Immune SA
发明人： Gregorio Del Val , Damien Névoltris
IPC分类号： A61K48/00 , C07K16/18 , C12N15/86
CPC分类号： A61K48/0058 , A61K48/0066 , C07K16/18 , C12N15/86 , C07K2317/622 , C12N2750/14143
摘要： A vector comprises a polynucleotide encoding an antibody or antibody fragment for use in a method of treatment of a disease or disorder of the central nervous system (CNS) in a subject, wherein the vector transduces or transfects cells of the blood brain barrier (BBB) and the transduced or transfected BBB cells express the antibody or antibody fragment resulting in delivery of the antibody or antibody fragment into the CNS, preferably into the brain parenchyma. Expression cassettes useful in such vectors may comprise from 5′ to 3′: at least one promoter operably linked to a first gene encoding a light chain of an antibody or antibody fragment and to a second gene encoding a heavy chain of the antibody or antibody fragment and further comprise an IRES after the first gene encoding the light chain of the antibody or antibody fragment and before the second gene encoding the heavy chain of the antibody or antibody fragment or a first promoter operably linked to a first gene encoding a light chain of an antibody or antibody fragment and a second promoter operably linked to a second gene encoding a heavy chain of the antibody or antibody fragment. The antibodies and antibody fragments thus produced may be of higher quality, displaying lower levels of aggregation and unwanted immunogenicity.

42. 发明公开

US20230391774A1 Novel Compounds 审中-公开
公开(公告)号：US20230391774A1
公开(公告)日：2023-12-07
申请号：US18248195
申请日：2021-10-11
申请人： AC Immune SA
发明人： Sreenivasachary Nampally , Emanuele Gabellieri , Veronique Dreyfus Dehlinger
IPC分类号： C07D471/04 , C07D413/14 , C07D413/04 , C07D413/12 , C07D417/12 , C07D513/04 , C07D519/00 , C07D498/04 , A61K45/06 , G01N33/50
CPC分类号： C07D471/04 , C07D413/14 , C07D413/04 , C07D413/12 , C07D417/12 , C07D513/04 , C07D519/00 , C07D498/04 , A61K45/06 , G01N33/5058 , G01N33/5038
摘要： The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of diseases, disorders and or abnormality associated with misfolding of Tau protein and/or pathological aggregation of Tau (Tubulin associated unit) protein including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD). The present invention also relates to processes for the preparation of said compounds, pharmaceutical compositions comprising said compounds, methods using said compounds, combinations comprising said compounds, medicaments containing them, and their uses in diseases, disorders and/or abnormalities associated with misfolding of Tau protein and/or pathological aggregation of Tau (Tubulin associated unit) protein.

43. 发明公开

US20230287050A1 Immunogenic Compounds 审中-公开
公开(公告)号：US20230287050A1
公开(公告)日：2023-09-14
申请号：US18014846
申请日：2021-08-04
申请人： AC Immune SA
发明人： Dorian Winter , Günther Staffler , Gergana Galabova , Eva Mihailovska , Petra Gruber , Katja Balazs
IPC分类号： C07K7/08 , A61P25/28 , A61K47/66 , A61K39/00
CPC分类号： C07K7/08 , A61P25/28 , A61K47/66 , A61K39/0007 , A61K38/00
摘要： An antigenic peptide comprises the structure X1-X2-X3-X4-X5-X6-X7-P-X9-X10-X11-X12 and is derived from amino acids 113-124 of alpha synuclein. Ac-cording to the structure: P is proline; X1 is L, K, A or S, wherein L is leucine, K is lysine, A is alanine and S is serine; X2 is E or S, wherein E and S are as defined above; X3 is D, E, K, N, A or S, wherein N is asparagine, D is aspartic acid and D, E, K, A and S are as defined above; X4 is M, A, S, L or K, wherein M is methionine and A, S, L and K are as defined above; X5 is P or A as defined above; X6 is V, A or S, wherein V is valine and A and S are as defined above; X7 is D or S as defined above; X9 is D or A as defined above; X10 is N, S or A, wherein N, S and A are as defined above; X11 is E, A or S, wherein E, A and S are as defined above; X12 is present or not and, if present, is A, K, V, S, or G wherein G is glycine and A, K, V and S are as defined above. The structure comprises at least one mutation compared to the wild type L-E-D-M-P-V-D-P-D-N-E-A sequence. The peptide does not comprise the dipeptide Y-E immediately following X12, wherein Y is tyrosine and E is as defined above. The peptides are conjugated to a suitable carrier and useful in treating synucleinopathies.

44. 发明公开

US20230201320A1 MIMOTOPES OF ALPHA-SYNUCLEIN AND VACCINES THEREOF FOR THE TREATMENT OF SYNUCLEINOPATHY 审中-公开
公开(公告)号：US20230201320A1
公开(公告)日：2023-06-29
申请号：US18057273
申请日：2022-11-21
申请人： AC Immune SA
发明人： Markus MANDLER , Harald WENINGER , Radmila SANTIC , Edith KOPINITS
IPC分类号： A61K39/00 , C07K16/42 , A61K47/64 , A61K9/00 , A61K38/17 , A61K47/02 , C07K14/47
CPC分类号： A61K39/0007 , A61K9/0019 , A61K38/1709 , A61K47/02 , A61K47/643 , C07K14/47 , C07K16/4241 , A61K38/00
摘要： A method of treating a synucleinopathy with a peptide

(C)DQPVLPD (SEQ ID NO: 59),

(C)DMPVLPD (SEQ ID NO: 60),

(C)DSPVLPD (SEQ ID NO: 61),

(C)DQPVLPDN (SEQ ID NO: 64),

(C)DMPVLPDN (SEQ ID NO: 65),

(C)DSPVLPDN (SEQ ID NO: 66),

(C)HDRPVTPD (SEQ ID NO: 70),

(C)DRPVTPD (SEQ ID NO: 71),

(C)DVPVLPD (SEQ ID NO: 72),

(C)DTPVYPD (SEQ ID NO: 73),

(C)DTPVIPD (SEQ ID NO: 74),

(C)HDRPVTPDN (SEQ ID NO: 75),

(C)DRPVTPDN (SEQ ID NO: 76),

(C)DVPVLPDN (SEQ ID NO: 78),

(C)DTPVYPDN (SEQ ID NO: 79),

(C)DQPVLPDG (SEQ ID NO: 81),

(C)DMPVLPDG (SEQ ID NO: 82),

(C)DSPVLPDG (SEQ ID NO: 83),

(C)DHPVHPDS (SEQ ID NO: 86),

(C)DMPVSPDR (SEQ ID NO: 87),

(C)DRPVYPDI (SEQ ID NO: 90),

(C)DHPVTPDR (SEQ ID NO: 91),

(C)DTPVLPDS (SEQ ID NO: 93),

(C)DMPVTPDT (SEQ ID NO: 94),

(C)DAPVTPDT (SEQ ID NO: 95),

(C)DSPWPDN (SEQ ID NO: 96),

(C)DLPVTPDR (SEQ ID NO: 97),

(C)DSPVHPDT (SEQ ID NO: 98),

(C)DAPVRPDS (SEQ ID NO: 99),

(C)DMPVWPDG (SEQ ID NO: 100),

(C)DRPVQPDR (SEQ ID NO: 102),

(C)YDRPVQPDR (SEQ ID NO: 103),

(C)DMPVDADN (SEQ ID NO: 105),

DQPVLPD(C) (SEQ ID NO: 106), and

DMPVLPD(C) (SEQ ID NO: 107.

45. 发明授权

US11555065B2 Anti-Tau antibodies and methods of use 有权
公开(公告)号：US11555065B2
公开(公告)日：2023-01-17
申请号：US17110969
申请日：2020-12-03
申请人： Genentech, Inc. , AC Immune SA
发明人： Oskar Adolfsson , Gai Ayalon , Isidro Hotzel , Danielle Marie Di Cara
IPC分类号： C07K16/18 , G01N33/68 , A61K39/395 , A61K45/06 , A61K39/00
摘要： The invention provides anti-Tau antibodies and methods of using the same.

46. 发明授权

US11534484B2 Mimotopes of alpha-synuclein and vaccines thereof for the treatment of synucleinopathy 有权
公开(公告)号：US11534484B2
公开(公告)日：2022-12-27
申请号：US16709999
申请日：2019-12-11
申请人： AC Immune SA
发明人： Markus Mandler , Harald Weninger , Radmila Santic , Edith Kopinits
IPC分类号： A61K38/00 , C07K7/00 , C07K4/00 , C07K14/00 , A61K49/00 , A61K38/17 , C07K14/47 , C07K14/475 , C07K14/48 , C07K19/00 , C07K14/435 , A61K39/00 , C07K16/42 , A61K47/64 , A61K9/00 , A61K47/02 , A61K39/395 , A61K39/385 , G01N33/68 , C07K16/18 , C07K7/06 , C07K7/08 , A61P25/28 , A61P25/16 , A61K31/00 , A61K47/42 , A61K47/69
摘要： A method of treating a synucleinopathy with a peptide (C)DQPVLPD (SEQ ID NO: 59), (C)DMPVLPD (SEQ ID NO: 60), (C)DSPVLPD (SEQ ID NO: 61), (C)DQPVLPDN (SEQ ID NO: 64), (C)DMPVLPDN (SEQ ID NO: 65), (C)DSPVLPDN (SEQ ID NO: 66), (C)HDRPVTPD (SEQ ID NO: 70), (C)DRPVTPD (SEQ ID NO: 71), (C)DVPVLPD (SEQ ID NO: 72), (C)DTPVYPD (SEQ ID NO: 73), (C)DTPVIPD (SEQ ID NO: 74), (C)HDRPVTPDN (SEQ ID NO: 75), (C)DRPVTPDN (SEQ ID NO: 76), (C)DVPVLPDN (SEQ ID NO: 78), (C)DTPVYPDN (SEQ ID NO: 79), (C)DQPVLPDG (SEQ ID NO: 81), (C)DMPVLPDG (SEQ ID NO: 82), (C)DSPVLPDG (SEQ ID NO: 83), (C)DHPVHPDS (SEQ ID NO: 86), (C)DMPVSPDR (SEQ ID NO: 87), (C)DRPVYPDI (SEQ ID NO: 90), (C)DHPVTPDR (SEQ ID NO: 91), (C)DTPVLPDS (SEQ ID NO: 93), (C)DMPVTPDT (SEQ ID NO: 94), (C)DAPVTPDT (SEQ ID NO: 95), (C)DSPVVPDN (SEQ ID NO: 96), (C)DLPVTPDR (SEQ ID NO: 97), (C)DSPVHPDT (SEQ ID NO: 98), (C)DAPVRPDS (SEQ ID NO: 99), (C)DMPVWPDG (SEQ ID NO: 100), (C)DRPVQPDR (SEQ ID NO: 102), (C)YDRPVQPDR (SEQ ID NO: 103), (C)DMPVDADN (SEQ ID NO: 105), DQPVLPD(C) (SEQ ID NO: 106), and DMPVLPD(C) (SEQ ID NO: 107.

47. 发明申请

US20220378801A1 NOVEL COMPOUNDS 有权
公开(公告)号：US20220378801A1
公开(公告)日：2022-12-01
申请号：US17621457
申请日：2020-06-22
申请人： AC Immune SA
发明人： Emanuele GABELLIERI , Jerome MOLETTE
IPC分类号： A61K31/5415 , C07D275/06 , C07D513/04 , C07D279/02 , C07D417/12 , A61K31/428 , A61K31/429 , A61K31/4436 , A61K31/437 , A61K39/395 , A61K45/06 , A61P37/06 , G01N33/50
摘要： The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of diseases, disorders and abnormalities responsive to modulation or inhibition of the activation of a component of the inflammasome pathway. In particular, the component of the inflammasome pathway is NLRP3 inflammasome. More particularly, the compounds of the present invention have the capability to inhibit the NLRP3 inflammasome. Further, the compounds of the present invention modulate, in particular, decrease IL-1 beta and/or IL-18 levels.

48. 发明申请

US20220226447A1 ANTI-ABETA VACCINE THERAPY 有权
公开(公告)号：US20220226447A1
公开(公告)日：2022-07-21
申请号：US17612921
申请日：2020-05-20
申请人： AC Immune SA
发明人： Andrea Pfeifer , Andreas Muhs (Deceased)
IPC分类号： A61K39/00 , A61K39/39 , A61P25/28
摘要： A liposomal vaccine composition comprising: a. A β-amyloid (Aβ)-derived peptide antigen displayed on the surface of the liposome that comprises, consists essentially of or consists of amino acids 1-15 of Aβ, b. An adjuvant comprising monophosphoryl lipid A (MPLA) is used for inducing an anti-Aβ immune response in a human subject without inducing a serious adverse event. The β-amyloid (Aβ)-derived peptide antigen (SEQ ID NO: 1) is administered in an amount of 300-2000 μg, preferably around 1000 μg. The MPLA is administered in an amount of 15-600 μg, preferably around 175 μg. The liposomal vaccine composition is administered intramuscularly or subcutaneously.

49. 发明申请

US20220127263A1 Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates 有权
公开(公告)号：US20220127263A1
公开(公告)日：2022-04-28
申请号：US17434918
申请日：2020-01-29
申请人： AC Immune SA
发明人： Sreenivasachary Nampally , Emanuele Gabellieri
IPC分类号： C07D471/04 , A61K45/06 , C07D498/04 , A61K31/5377
摘要： The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).

50. 发明申请

US20220025023A1 MISFOLDED TDP-43 BINDING MOLECULES 有权
公开(公告)号：US20220025023A1
公开(公告)日：2022-01-27
申请号：US16959385
申请日：2019-01-04
申请人： AC Immune SA
发明人： Tamara Seredenina , Oskar Adolfsson
IPC分类号： C07K16/18 , A61K47/68 , G01N33/68 , A61K45/06
摘要： The present invention is in the field of transactive response DNA binding protein with a molecular weight of 43 kDa (TARDB or also TDP-43). The invention relates to TDP-43 specific binding molecules, in particular to anti-TDP-43 antibodies or an antigen-binding fragment or a derivative thereof and uses thereof. The present invention provides means and methods to diagnose, prevent, alleviate and/or treat a disorder and/or abnormality associated with misfolded TDP-43 including but not limited to frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD, sporadic and familial), and/or Parkinson's disease (PD). The present invention provides modified conformation-specific antigenic peptides and peptide fragments derived from the TDP-43 protein and the antibodies obtainable by said peptides or fragments for use in the diagnosis, prevention, alleviation and/or treatment of TDP-43-related disorders and/or abnormalities.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式